Solu Therapeutics Valued at $100M After Series A Investment
Deal News | Apr 10, 2025 | DCVC Management Co LLC
Solu Therapeutics, a Boston-based clinical-stage biotech company, has been valued at $100 million following the successful closure of a $41 million Series A funding round. The funding round was backed by investors including new participant Eli Lilly, providing Solu with over two years of operational runway. The company has specialized in utilizing small molecule technology and therapeutic antibodies, acquired from GSK, to create treatments for cancers and immunological diseases. Solu is currently running a Phase 1 clinical trial to test their platform on hematologic malignancies such as resistant or refractory chronic myelomonocytic leukemia. Founded in 2023 with the support of VC firm Longwood Fund, Solu's CEO, Philip Vickers, has indicated the company may begin seeking additional Series B funding later this year should clinical results be promising. Solu is also exploring potential partnerships with pharmaceutical companies to enhance its platform's development efforts.
Sectors
- Biotechnology
- Pharmaceuticals
- Venture Capital
Geography
- United States – Solu Therapeutics is based in Boston, and the venture capital activities by DCVC and Longwood Fund also pertain to entities operating in the U.S.
- United Kingdom – The technology platform that Solu Therapeutics acquired was licensed from GSK, a British multinational pharmaceutical company.
Industry
- Biotechnology – The article focuses on Solu Therapeutics, a clinical-stage biotech firm, discussing its advances in small molecule and therapeutic antibody technologies for cancer and immunology.
- Pharmaceuticals – Solu Therapeutics is involved in discussions for partnerships with other pharmaceutical companies, indicating an intersection with the pharmaceutical industry.
- Venture Capital – The article discusses DCVC and Longwood Fund's involvement in providing capital to Solu Therapeutics, highlighting venture capital activities.
Financials
- $100 million – Valuation of Solu Therapeutics following the Series A funding round.
- $41 million – The amount raised by Solu Therapeutics in its Series A funding round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Solu Therapeutics | Target Company | Company | A clinical-stage biotech firm focused on cancer and immunology, currently valued at $100 million. |
| DCVC Management Co LLC | Investor | Company | A private equity firm involved in Solu Therapeutics' Series A funding. |
| Philip Vickers | CEO of Solu Therapeutics | Person | Provides strategic direction and project management for Solu Therapeutics' operations. |
| Eli Lilly | New Investor | Company | A pharmaceutical company that participated in the Series A funding round for Solu Therapeutics. |
| GSK | Technology Licensor | Company | A pharmaceutical giant from which Solu Therapeutics acquired the platform technology. |
| Longwood Fund | Venture Capital Firm | Company | A Boston-based VC firm that helped facilitate Solu Therapeutics' acquisition of technology from GSK. |